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Letter to the Editor

Common SPINK-1 genetic mutations do not predispose to Crohn disease
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To the Editor,
Genetic factors may be important in Crohn disease
(CD) risk and progression (1). The detection of linkage
on chromosome 16 led to identification of the CARD15/
NOD2 gene as a susceptibility gene for CD (2).
Pancreatic secretory trypsin inhibitor, also known
as serine protease inhibitor Kazal type 1 (SPINK-1), is a
56-amino acid peptide that protects the pancreas from
autodigestion (3). SPINK-1 expression occurs in tissues
other than the pancreas including the liver, the mucosa
of the stomach, and the small and large intestines (4,5).
The SPINK-1 gene, located on chromosome 5q32, is close
to one of the CD susceptibility loci (6). The association
of pancreatic disorders with inflammatory bowel disease
(IBD), the role of the SPINK-1 molecule in epithelial
and mucosal protection, and the genetic location of the
SPINK-1 gene close to one of the CD susceptibility loci
prompted us to perform SPINK-1 gene genetic association
analyses to ascertain its possible role in CD pathogenesis.
Patients admitted to the Ege University Inflammatory
Bowel Disease Outpatient Clinic between January 2009
and January 2010 were evaluated and 56 CD patients and
80 healthy volunteers were included in the study. For each
patient disease activity was assessed by the CD activity
index (CDAI) and disease localization was classified
according to the Vienna classification (7). Common genetic
mutations in the third exon of the SPINK-1 gene were
analyzed by direct sequencing method as reported in the
literature. The associations between phenotypic features of
the disease and genotypic variations were evaluated (8).
The study was approved by the local ethics committee and
was performed in accordance with the ethical standards
laid down in the 1964 Declaration of Helsinki.
The mean age of CD patients at the time of diagnosis
was 36.2 ± 15.2 years. Mean duration of CD disease was 6.5
± 5 years when patients were included in the study. CD was
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located to the ileocolic segment in 24 (L3), the ileal segment
in 21 (L1), and the colon in 10 patients (L2). The upper
gastrointestinal system was affected in one subject (L4).
Patients were receiving mesalazine and corticosteroids
according to their disease location and activity. Three
patients were on azothiopurine treatment due to steroid
side effects. Nine patients had stricturing disease and 8
had penetrating disease. Extraintestinal manifestations
including seronegative arthritis (n = 4), amyloidosis (n
= 1), and erythema nodosum (n = 5) were diagnosed in
10 CD patients. None of the patients had acute or chronic
pancreatitis. Neither N34S mutation nor P55S mutation
was found in the SPINK-1 gene third exon in CD patients.
One control subject had a homozygous mutation at the
N34S location (Figure). The allele frequency of N34S was
1% in healthy controls. No other rare mutations including
D50E, Y54H, R65Q, and K66N of the SPINK-1 gene were
detected in the studied groups.
Susceptibility for CD is predominantly determined
by genetic factors and the complex inheritance patterns
suggest the interaction of multiple genes. Serine protease
inhibitors synthesized within the gut maintain mucosal
integrity and/or stimulate repair after injury (9). Despite
the known role of the SPINK-1 molecule in epithelial and
mucosal protection and the important genetic location
close to the CD IBD5 susceptibility locus, our findings
showed that common SPINK-1 mutations are not found
in CD patients in the Turkish population. However, the
number of subjects in this study group was too small to
rule out the association between SPINK-1 mutations and
CD. It is also suggested that SPINK-1 mutations are rare in
the healthy Turkish population. Extensions of genetic and
expression analysis to all other serine protease inhibitors
in different populations are warranted in further studies to
clarify the possible role of SPINK molecules in CD.
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Figure. Sequence analysis of subjects: mutation at N34S is seen in one of the healthy
controls.
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